Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ACTIVE NOT RECRUITING

NCT04035486

PHASE3

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

Sponsor: AstraZeneca

View on ClinicalTrials.gov

Summary

The reason for the study is to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO®) when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of locally advanced or metastatic non-small cell lung cancer. Some lung cancers are due to mutations in the Deoxyribonucleic acid (DNA) which, if known, can help physicians decide the best treatment for their patients. One type of mutation can occur in the gene that produces a protein on the surface of cells called the Epidermal Growth Factor Receptor (EGFR). Osimertinib is an Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets Epidermal Growth Factor Receptor (EGFR) mutations. Unfortunately, despite the benefit observed for patients treated with osimertinib, the vast majority of cancers are expected to develop resistance to the drug over time. The exact reasons why resistance develops are not fully understood but based upon clinical research it is hoped that combining osimertinib with another type of anti-cancer therapy known as chemotherapy will delay the onset of resistance and the worsening of a patient's cancer. In total the study aims to enroll approximately 586 patients, consisting of approximately 30 patients who will participate in a safety run-in component of the trial, and approximately 556 who will receive osimertinib alone or osimertinib in combination with chemotherapy in the main trial. In the main part of the trial there is a one in two chance of receiving osimertinib alone, and the treatment is decided at random by a computer. The study involves a Screening Period, Treatment Period, and Follow up Period. Whilst receiving study medication, it is expected patients will attend, on average, approximately 15 visits over the first 12 months and then approximately 4 visits per year afterwards. Each visit will last about 2 to 6 hours depending on the arrangement of medical assessments by the study centre.

Official title: A Phase III, Open-label, Randomized Study of Osimertinib With or Without Platinum Plus Pemetrexed Chemo, as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2).

Key Details

Gender

All

Age Range

18 Years - 110 Years

Study Type

INTERVENTIONAL

Enrollment

587

Start Date

2019-07-02

Completion Date

2026-12-22

Last Updated

2025-10-10

Healthy Volunteers

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Osimertinib

Drug: Osimertinib (Oral) Other Names: AZD9291

DRUG

Pemetrexed/Carboplatin

Drug: Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.

DRUG

Pemetrexed/Cisplatin

Drug: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.

Inclusion Criteria: 1. Male or female, at least 18 years of age; patients from Japan at least 20 years of age. 2. Pathologically confirmed non-squamous Non-Small Cell Lung Cancer (NSCLC). NSCLC of mixed histology is allowed. 3. Newly diagnosed locally advanced (clinical stage IIIB, IIIC) or metastatic Non-Small Cell Lung Cancer (NSCLC) (clinical stage IVA or IVB) or recurrent Non-Small Cell Lung Cancer (NSCLC) not amenable to curative surgery or radiotherapy. 4. The tumor harbors 1 of the 2 common epidermal growth factor receptor (EGFR) mutations known to be associated with Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) sensitivity (Ex19del or L858R), either alone or in combination with other epidermal growth factor receptor (EGFR) mutations, which may include T790M. 5. Patients must have untreated advanced Non-Small Cell Lung Cancer (NSCLC) not amenable to curative surgery or radiotherapy. 6. WHO PS of 0 to 1 at screening with no clinically significant deterioration in the previous 2 weeks. 7. Life expectancy \>12 weeks at Day 1. 8. Willing to use contraception as appropriate during the study and for a period of time after discontinuing study treatment. Exclusion Criteria: 1. Spinal cord compression; and unstable brain metastases, with stable brain metastases who have completed definitive therapy, are not on steroids, and have a stable neurological status for at least 2 weeks after completion of the definitive therapy and steroids can be enrolled. Patients with asymptomatic brain metastases can be eligible for inclusion if in the opinion of the Investigator immediate definitive treatment is not indicated 2. Past medical history of Interstitial Lung Disease (ILD), drug-induced Interstitial Lung Disease, radiation pneumonitis that required steroid treatment, or any evidence of clinically active Interstitial Lung Disease. 3. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the Investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol, or active infection including Hep. B, Hep. C and HIV. Screening for chronic conditions is not required. Active infection will include any patients receiving treatment for infection. 4. QT prolongation or any clinically important abnormalities in rhythm. 5. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values: * Absolute neutrophil count below the lower limit of normal (\<LLN) * Platelet count below the LLN * Hemoglobin \<90 g/L. The use of granulocyte colony stimulating factor support, platelet transfusion and blood transfusions to meet these criteria is not permitted. * ALT \>2.5 x the upper limit of normal (ULN) if no demonstrable liver metastases or \>5 x ULN in the presence of liver metastases * AST \>2.5 x ULN if no demonstrable liver metastases or \>5 x ULN in the presence of liver metastases * Total bilirubin \>1.5 x ULN if no liver metastases or \>3 x ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases * Creatinine clearance \<60 mL/min calculated by Cockcroft and Gault equation or 24 hour urine collection (refer to Appendix I for appropriate calculation) 6. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib. 7. Prior treatment with any systemic anti-cancer therapy for advanced Non-Small Cell Lung Cancer (NSCLC) not amenable to curative surgery or radiation including chemotherapy, biologic therapy, immunotherapy, or any investigational drug. Prior adjuvant and neo-adjuvant therapies (chemotherapy, radiotherapy, immunotherapy, biologic therapy, investigational agents), or definitive radiation/chemoradiation with or without regimens including immunotherapy, biologic therapies, investigational agents are permitted as long as treatment was completed at least 12 months prior to the development of recurrent disease. 8. Prior treatment with an Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). 9. Major surgery within 4 weeks of the first dose of investigational product (IP). Procedures such as placement of vascular access, biopsy via mediastinoscopy or biopsy via video assisted thoracoscopic surgery are permitted. 10. Radiotherapy treatment to more than 30% of the bone marrow or( with a wide field of radiation within 4 weeks of the first dose of investigational product (IP). 11. History of hypersensitivity to active or inactive excipients of investigational product (IP) or drugs with a similar chemical structure or class to investigational product (IP).

Locations (153)

Research Site

Bellflower, California, United States

Research Site

Fullerton, California, United States

Research Site

La Jolla, California, United States

Research Site

Santa Monica, California, United States

Research Site

Santa Rosa, California, United States

Research Site

West Hollywood, California, United States

Research Site

Whittier, California, United States

Research Site

Orlando, Florida, United States

Research Site

Tampa, Florida, United States

Research Site

Kansas City, Kansas, United States

Research Site

Louisville, Kentucky, United States

Research Site

Boston, Massachusetts, United States

Research Site

Henderson, Nevada, United States

Research Site

Albany, New York, United States

Research Site

Canton, Ohio, United States

Research Site

Philadelphia, Pennsylvania, United States

Research Site

Pittsburgh, Pennsylvania, United States

Research Site

Pittsburgh, Pennsylvania, United States

Research Site

Houston, Texas, United States

Research Site

San Antonio, Texas, United States

Research Site

Blacksburg, Virginia, United States

Research Site

Fairfax, Virginia, United States

Research Site

Vancouver, Washington, United States

Research Site

Buenos Aires, Argentina

Research Site

Buenos Aires, Argentina

Research Site

CABA, Argentina

Research Site

CABA, Argentina

Research Site

Ciudad de Buenos Aires, Argentina

Research Site

Córdoba, Argentina

Research Site

Santa Fe, Argentina

Research Site

Camperdown, Australia

Research Site

Chermside, Australia

Research Site

Elizabeth Vale, Australia

Research Site

Heidelberg, Australia

Research Site

Kogarah, Australia

Research Site

Melbourne, Australia

Research Site

Barretos, Brazil

Research Site

Florianópolis, Brazil

Research Site

Londrina, Brazil

Research Site

Porto Alegre, Brazil

Research Site

Ribeirão Preto, Brazil

Research Site

São José do Rio Preto, Brazil

Research Site

São Paulo, Brazil

Research Site

São Paulo, Brazil

Research Site

Vitória, Brazil

Research Site

Calgary, Alberta, Canada

Research Site

Edmonton, Alberta, Canada

Research Site

Toronto, Ontario, Canada

Research Site

Santiago, Chile

Research Site

Santiago, Chile

Research Site

Temuco, Chile

Research Site

Viña del Mar, Chile

Research Site

Beijing, China

Research Site

Beijing, China

Research Site

Beijing, China

Research Site

Changchun, China

Research Site

Changsha, China

Research Site

Chengdu, China

Research Site

Chongqing, China

Research Site

Guangzhou, China

Research Site

Haikou, China

Research Site

Hangzhou, China

Research Site

Hangzhou, China

Research Site

Harbin, China

Research Site

Hefei, China

Research Site

Jinan, China

Research Site

Nanjing, China

Research Site

Shanghai, China

Research Site

Shanghai, China

Research Site

Shenyang, China

Research Site

Ürümqi, China

Research Site

Wuhan, China

Research Site

Xi'an, China

Research Site

Zhengzhou, China

Research Site

Olomouc, Czechia

Research Site

Ostrava - Vitkovice, Czechia

Research Site

Prague, Czechia

Research Site

Prague, Czechia

Research Site

Bordeaux, France

Research Site

Lyon, France

Research Site

Montpellier, France

Research Site

Villejuif, France

Research Site

Belagavi, India

Research Site

Bengaluru, India

Research Site

Gūrgaon, India

Research Site

Kolkata, India

Research Site

New Delhi, India

Research Site

Pune, India

Research Site

Bunkyō City, Japan

Research Site

Bunkyō City, Japan

Research Site

Fukuoka, Japan

Research Site

Hidaka-shi, Japan

Research Site

Himeji-shi, Japan

Research Site

Iwakuni-shi, Japan

Research Site

Kanazawa, Japan

Research Site

Kashiwa, Japan

Research Site

Kōtoku, Japan

Research Site

Osaka, Japan

Research Site

Sakaishi, Japan

Research Site

Sapporo, Japan

Research Site

Sendai, Japan

Research Site

Sunto-gun, Japan

Research Site

Yokohama, Japan

Research Site

Arequipa, Peru

Research Site

Lima, Peru

Research Site

Lima, Peru

Research Site

Lima, Peru

Research Site

San Isidro, Peru

Research Site

Cebu City, Philippines

Research Site

Davao City, Philippines

Research Site

Iloilo City, Philippines

Research Site

Las Piñas, Philippines

Research Site

Legaspi, Philippines

Research Site

Quezon City, Philippines

Research Site

Quezon City, Philippines

Research Site

Moscow, Russia

Research Site

Moscow, Russia

Research Site

Murmansk, Russia

Research Site

Saint Petersburg, Russia

Research Site

Saint Petersburg, Russia

Research Site

Saint Petersburg, Russia

Research Site

Syktyvkar, Russia

Research Site

Bratislava, Slovakia

Research Site

Košice, Slovakia

Research Site

Poprad, Slovakia

Research Site

Johannesburg, South Africa

Research Site

Port Elizabeth, South Africa

Research Site

Rondebosch, South Africa

Research Site

Cheongju-si, South Korea

Research Site

Goyang-si, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Changhua, Taiwan

Research Site

Hualien City, Taiwan

Research Site

Kaohsiung City, Taiwan

Research Site

Taichung, Taiwan

Research Site

Taichung, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taipei, Taiwan

Research Site

Bangkok, Thailand

Research Site

Bangkok, Thailand

Research Site

Bangkok, Thailand

Research Site

Hat Yai, Thailand

Research Site

Khon Kaen, Thailand

Research Site

Muang, Thailand

Research Site

Cambridge, United Kingdom

Research Site

Leicester, United Kingdom

Research Site

Liverpool, United Kingdom

Research Site

Maidstone, United Kingdom

Research Site

Manchester, United Kingdom

Research Site

Hanoi, Vietnam

Research Site

Ho Chi Minh City, Vietnam

Clinical Research Directory

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (153)